SCHEMBL14764110

SCHEMBL14764110

N[C@H](COc1ccc2ncc(-c3cc4cc(Cl)ccc4o3)n2n1)c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 20/20 0.60
MKNK2 Q9HBH9 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14763738 0.90 MKNK1 (0.65) MKNK1MKNK2
SCHEMBL18901496 0.90 MKNK1 (0.65) MKNK1MKNK2
SCHEMBL14771362 0.90 MKNK1 (0.69) MKNK1MKNK2
SCHEMBL14764108 0.90 MKNK1 (0.69) MKNK1MKNK2
SCHEMBL18901484 0.90 MKNK1 (0.69) MKNK1MKNK2
SCHEMBL18901563 0.87 MKNK1 (0.67) MKNK1MKNK2
SCHEMBL14771503 0.87 MKNK1 (0.67) MKNK1MKNK2
SCHEMBL15019844 0.86 MKNK1 (0.60) MKNK1MKNK2
SCHEMBL19316165 0.86 MKNK1 (0.60) MKNK1MKNK2
SCHEMBL16278330 0.86 MKNK1 (0.60) MKNK1MKNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017157418-A1 COMBINATION OF MKNK1-INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-09-21 WO claimed
EP-2758401-B1 AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES BAYER IP GMBH (DE) 2017-05-31 EP claimed
US-20140296231-A1 AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-10-02 US claimed
EP-2758401-A1 AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES Bayer Intellectual Property GmbH (DE) 2014-07-30 EP claimed
WO-2013034570-A1 AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-03-14 WO claimed
EP-2758401-B1 AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES BAYER IP GMBH (DE) 2017-05-31 EP disclosed
EP-2758401-B1 AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES BAYER IP GMBH (DE) 2017-05-31 EP disclosed
US-9499547-B2 Amino-substituted imidazopyridazines BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-11-22 US disclosed
US-9499547-B2 Amino-substituted imidazopyridazines BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-11-22 US disclosed
US-9499547-B2 Amino-substituted imidazopyridazines BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-11-22 US disclosed
US-20140296231-A1 AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-10-02 US disclosed
US-20140296231-A1 AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-10-02 US disclosed
US-20140296231-A1 AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-10-02 US disclosed
EP-2758401-A1 AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES Bayer Intellectual Property GmbH (DE) 2014-07-30 EP disclosed
WO-2013034570-A1 AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-03-14 WO disclosed
WO-2013034570-A1 AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-03-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296231-A1 AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES VEGFA, CCND2, CCND1 MKNK1 2406/4885MKNK2 2802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.